IO Biotech
Signal active
Organization
Contact Information
Overview
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
About
Industries
Biotechnology, Health Care, Therapeutics
Founded
2014
Employees
51-100
Headquarters locations
Europe
Social
N/A
Profile Resume
IO Biotech headquartered in Europe, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $10.5B in funding across 60 round(s). With a team of 51-100 employees, IO Biotech is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - IO Biotech, raised $11.8M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
2
Lead Investors
0
Total Funding Amount
$175.0M
Details
3
IO Biotech has raised a total of $175.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 154.5M | ||
| 2021 | Late Stage Venture | |||
| 2016 | Early Stage Venture | 11.8M |
Investors
IO Biotech is funded by 29 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| IO Biotech | - | FUNDING ROUND - IO Biotech | 11.8M |
| Novo Nordisk | - | FUNDING ROUND - Novo Nordisk | 11.8M |
| IO Biotech | - | FUNDING ROUND - IO Biotech | 11.8M |
| Lundbeckfonden Ventures | - | FUNDING ROUND - Lundbeckfonden Ventures | 11.8M |
Recent Activity
There is no recent news or activity for this profile.